Sign in
TerminatedNo phase

Blood Samples to Identify Biomarkers of Busulfan

Key facts

Who runs it
Fred Hutchinson Cancer Center
Where
Seattle, United StatesSee the site
Trial code
Status
Terminated
People taking part
139 people enrolled
Started
Nov 2014
Ended
7 Oct 2024
Type of study
Observational
Record updated
3 March 2025
Why it stopped
Study terminated due to end of funding

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Scheduled to receive targeted intravenous busulfan (any dose, any number of doses, any dosing frequency) as part of their hematopoietic stem cell transplant conditioning
  • Weight > 21kg

Who cannot take part

  • Life expectancy severely limited by diseases other than malignancy
  • Unable to read English
  • Female patients who are pregnant or breastfeeding

Where in United States

  • University of WashingtonSeattle, United States

About the trial

What the trial wants to find out

Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance.

Read full original descriptionShow less

Specific Aim 2: To characterize IV BU metabolism by metabolomics.

Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics
Record updated
3 March 2025